TCR1672 not checked
Beijing Tide Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three…”In the company’s words, NCT06213363 on ClinicalTrials.gov
- Tested for
- Refractory Chronic Cough
- Main trialPhase 1/2
- “This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory chronic cough.”In the company’s words, NCT06213363 on ClinicalTrials.gov
Other drugs for Refractory Chronic Cough
- CamlipixantBellus Health Inc. - a GSK company · Phase 3
- SC0032Sensory Cloud, Inc. · Phase 2
- NAL ERTrevi Therapeutics · Phase 2
- HW091077Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Phase 2
- ME-015Melius Pharma AB · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Unknown | Oct 2024 | A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026